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See Article, pages 859–865Infection with hepatitis C virus (HCV) is characterized by two dif-
ferent outcomes. Approximately 30% of HCV-infected patients
spontaneously resolve HCV infection while the others fail to con-
trol the infection. Once chronic HCV infection is established, anti-
viral therapy based on pegylated interferon alpha (PEG-IFNa) and
ribavirin achieves viral clearance in only 30–50% of cases [6].
Genome-wide association studies (GWAS) indicated that host
genetic variation plays a key determinant in natural and treat-
ment-induced control of HCV infection. Independent GWAS stud-
ies consistently identiﬁed variants within the IL28B gene region
that are strongly associated with spontaneous HCV clearance
and hepatitis C treatment-induced viral clearance [4,10,13,18–
20]. However, the mechanism by which IL28B variants inﬂuence
viral clearance remains undetermined. The IL28B gene forms a
cytokine gene cluster with IL28A and IL29 on human chromosome
19. IL29, IL28A, and IL28B are also known as IFNk1, IFNk2, and
IFNk3, respectively. They are type III IFNs with antiviral activity.
IL28B is highly homologous to IL28A (96%) and shows 81% homol-
ogy with IL29. Type III IFNs have biological activities that are sim-
ilar to those of type I IFNs (IFNa/b), although they share very little
sequence homology. Type III IFN expression depends on the same
stimuli (viral infection, Toll-like receptor ligands) and signal
transduction pathways as those involved in type I IFN expression,
which leads to the induction of several hundred interferon-stim-
ulated genes (ISGs), such as Mx1, OAS or IFIT [7,16] (Fig. 1).
In the current issue of the Journal of Hepatology, Langhans
et al. performed a cross-sectional analysis of IFNk serum levels
in HCV-infected patients with different outcomes and stratiﬁed
their results with the single nucleotide polymorphism (SNP)
rs12979860 that is located 3 kb upstream of the IL28B gene.
GWAS studies carried out by Ge et al. [4] and McCarthy et al.
[10] found a striking correlation between carriers with the
rs12979860 CC genotype and sustained virological response
(SVR) rates. The protective rs12979860 CC genotype was not only
associated with signiﬁcantly higher SVR rates in patients with
chronic HCV infection but also predicted spontaneous HCV
clearance [20]. The study by Langhans et al. included 60 treat-
ment-naive patients with chronic HCV infection, 19 patients withJournal of Hepatology 20
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ance, and 26 healthy individuals. The authors found that IL28
A/B and IL29 serum levels were signiﬁcantly higher in carriers
of the protective rs12979860 CC genotype than in carriers of
the TT genotype when all study groups were analyzed as a single
population. Because IL28A/B serum levels were rather low or
undetectable, the authors focused exclusively on IL29 in their
subsequent studies. When IL29 serum levels were analyzed with
respect to the different outcomes, patients with chronic HCV
infection displayed signiﬁcantly lower IL29 serum levels than
patients with acute hepatitis C, patients with self-limited HCV,
and healthy individuals. IL29 serum levels were consistently
and signiﬁcantly higher in patients with resolved HCV infection
than in patients with chronic HCV infection, even when the
IL29 serum levels were stratiﬁed for the different rs12979860
genotypes. Next, Langhans et al. conducted a prospective study
of serum samples from patients who had acute hepatitis C. The
authors found that patients who resolved their acute infection
had signiﬁcantly higher IL29 serum levels than patients who pro-
gressed to chronicity. When IL29 serum levels were stratiﬁed
with the different rs12979860 genotypes, carriers of the CC geno-
types had consistently higher IL29 levels than carriers of the TT
genotype. Finally, there was a trend (p = 0.053) to higher IL29 lev-
els in HCV resolver with the protective rs12979860 CC genotype
than to HCV non-resolver with the CC genotype. Accordingly, the
authors concluded that high IFNk levels may predispose to HCV
clearance and that the rs12979860 CC genotype may contribute
to viral clearance due to enhanced IFNk expression.
The work by Langhans et al. provides initial insights into the
role of IFNk in HCV clearance and the functional consequences
of the IL28B polymorphism. The strong association between high
IL29 serum levels and spontaneous HCV clearance suggests that
IL29 has unique antiviral effects that are important for the control
of HCV infection. In fact, IFNk exerts antiviral effects on HCV rep-
lication with kinetics and efﬁciency similar to IFNa, as shown in
the HCV replicon system and the infectious HCV cell culture
model [9,14]. However, IFNk treatment could not entirely elimi-
nate HCV replication, suggesting that IFNk induced genes fail to
completely abrogate viral replication. IFNk signaling is initiated
through a membrane receptor system distinct from that of IFNa.
The IFNk receptor complex consists of IFNLR1 (IFNk receptor 1;
also known as IL-28Ra) and IL-10 receptor 2 (IL-10R2), while11 vol. 54 j 844–847
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Fig. 1. Interferon lambda pathway. HCV-infected cells recognize viral RNA through cellular sensors, e.g. Toll-like receptor 3 (TLR3) and cytoplasmic receptor RIG-I.
Stimulation of these receptors leads to the activation of transcription factors such as interferon-regulatory factor 3 (IRF-3) and IRF-7. Binding sites for IRF-3 and IRF-7 have
been identiﬁed in the promoter region for IFNk and are essential for IFNk transcription. The three IFNk subtypes (IL28A, IL28B, and IL29) exert their activity through a
receptor composed of interleukin-10 receptor (IL-10R2) and IFNk receptor 1 (IFNLR1 or IL28aR). This results in the activation of the JAK-STAT pathway and the induction of
interferon-stimulated genes (ISGs), e.g. ISG15, Mx1, and OAS. ISGs products have been shown to interrupt HCV replication through processes that include suppression of
viral replication and protein synthesis. Polymorphisms upstream of the IL28B gene (rs12979860, rs8099917) are associated with spontaneous and treatment-induced HCV
clearance. IL28B polymorphism appears to affect the expression of IFNk and ISGs by pathways that are yet unknown.
JOURNAL OF HEPATOLOGYthe IFNa receptor is constructed from the ubiquitously expressed
IFNAR1 and IFNAR2c subunits [7]. Unlike the response to IFNa,
the response to IFNk appears to be restricted to epithelial cells
and is notably absent in most hematopoietic cells due to weak
or absent IL28Ra expression [21]. Surprisingly, in mice, the liver
responded poorly to IFNk and expressed low amounts of IL28Ra
[14,17], suggesting that the IFNk response plays only a minor role
in the host defense against viruses that infect the liver. However,
Doyle et al. detected IL28Ra protein expression in the livers of
HCV-infected patients, as well as transcriptional induction of
OAS and Mx1 following IL29 stimulation of primary human hepa-
tocytes [2]. Furthermore, a recently completed phase 1b study
with PEG-IL29 in patients who were chronically infected with
HCV genotype 1 showed promising results. IL29 was well toler-
ated without the toxicities typically associated with IFNa and
exhibited potent antiviral activity [12]. IFNa treatment triggers
ﬂu-like symptoms, depression, and hematopoietic side effects.
The greater cell-speciﬁc expression pattern for the IFNk receptors
may explain the fewer side effects observed during IFNk treat-Journal of Hepatology 201ment. Although these studies support the view that IFNk pos-
sesses antiviral effects against HCV, further research is needed
to determine the precise role of endogenous IFNk in HCV clear-
ance and to evaluate how much antiviral defense is added by
the IFNk system to the very potent IFNa/b system.
Cytokines are powerful mediator and communication mole-
cules. However, the signiﬁcance of cytokine levels in the serum
is often difﬁcult to interpret. With few exceptions, the biological
half-life of cytokines in vivo is short. The short in vivo half-life is
the result of binding to high-afﬁnity receptors or plasma proteins,
as well as of proteolytic degradation. It was, therefore, surprising
that Langhans et al. detected IL29 at steady state levels and that
high levels of this cytokine turned out to be an early predictor of
HCV clearance. The data are difﬁcult to reconcile with the obser-
vation that patients who respond poorly to IFNa therapy have a
high pre-therapy level of intrahepatic ISG expression [1,3,15]. It
will be, therefore, important to determine the spectrum of ISG
expression in HCV-infected patients with elevated IL29 levels.
IFNs are induced to varying degrees in most cell types, with mye-1 vol. 54 j 844–847 845
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loid and plasmacytoid dendritic cells (mDCs and pDCs) being the
two most prominent sources of these cytokines. IFNs released by
DCs not only have potent antiviral activity but also support sub-
sequent steps of antiviral immunity, such as the activation of nat-
ural killer and T cell-mediated cytotoxicity. Previous studies
reported that HCV interferes with the IFNa production in pDCs
(for review, see [8]). Additional experiments by Langhans et al.
suggest that HCV also affects IFNk production in mDCs and pDCs.
The presence of the HCV envelope glycoprotein E2 and NS3 pro-
tein, but no other recombinant HCV proteins, signiﬁcantly
reduced IL29 production by DC subsets following stimulation
with TLR3 and poly I:C. The ﬁnding that HCV might have devel-
oped strategies to attenuate the IL29 response in DCs underscores
the importance of this cytokine for antiviral protection. Studies
with the infectious HCV cell culture model will be required to
demonstrate conclusively that HCV counteracts the IFNk
response in DCs and to investigate the underlying mechanism.
IFNk may also act on DCs through an autocrine feedback loop.
Diverse immunomodulatory effects of IFNk on DCs have been
reported, including maturation and differentiation of DCs [11].
Therefore, it will be very interesting to investigate whether
HCV-induced impairment of IFNk production has an impact on
the HCV antigen presentation function by DCs and the generation
of antiviral cellular immune responses.
Polymorphism may have a functional role by inﬂuencing pro-
moter activity (gene expression), messenger RNA (mRNA) confor-
mation (stability), and protein stability (half life). Since the
identiﬁed SNPs are quite far from the IL28B gene, the direct func-
tional role of IL28B polymorphisms on IFNk gene expression and
function is uncertain. At the present, IFNk gene expression data
have yielded conﬂicting results (Table 1). Langhans et al. found
signiﬁcantly higher IL28A/IL28B and IL29 serum levels in carriers
of the protective rs12979860 CC genotype. Ge et al. [4] found no
association between rs12979860 CC genotype and increased
IL28B mRNA expression in peripheral blood mononuclear cells
(PBMCs). Suppiah et al. [18] and Tanaka et al. [19] reported that
SNP rs8099917, a SNP 8 kb upstream of the IL28B gene and asso-
ciated signiﬁcantly with treatment failure, was associated with
lower IL28B mRNA expression in PBMCs. Honda et al. [5] exam-
ined IL28B mRNA expression and ISG induction in the livers of
patients who had chronic HCV infection. They did not ﬁnd signif-
icant differences in hepatic IL28B mRNA expression between car-
riers with rs8099917 risk and protective genotypes. However,
hepatic ISG induction was signiﬁcantly higher in patients who
had the rs8099917 risk genotype than in those who had the pro-
tective genotype. This suggests that the IL28B polymorphism dif-
ferentially regulates the expression of ISGs in the liver.
Unfortunately, the currently available data are insufﬁcient to
ﬁrmly delineate the effect of the IL28B polymorphism on IFNkTable 1
Associations between carriage of IL28B risk alleles and IFNI or ISG expression.
(See below-mentioned references for further information).
Serum
PBMCs (mRNA)
Liver (mRNA)
reduced Langhans et al. [22]
reduced Suppiah et al. [18], Tanaka et al. [19]
unchanged Ge et al. [4]
unchanged Honda et al. [5]
n.d.
n.d.
n.d.
increased Honda et al.[5] 
Compartment IFN λ expression ISG expression
Effects of IL28B risk alleles on
n.d. = not determined.
846 Journal of Hepatology 201expression. Further studies are needed to clarify the impact of
the IL28B polymorphism on the regulation of antiviral signaling
pathways in hepatocytes, as well as innate immune cells, such
as DCs and macrophages.
Elucidating the functional consequences of the IL28B polymor-
phism continues to be a difﬁcult challenge. SNPs within the IL28B
gene region appear to affect IFNk and ISG induction by pathways
that are yet unknown. A better understanding of the cross-talk
between the IFNa/b and IFNk response and the impact of IFNk
on the adaptive immune response may allow us to peek behind
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